Agent Hub

Identifies SBIR/STTR grants, NIH program announcements, and foundation funding. Scores opportunities, drafts specific aims, and builds application timelines.

• Search grant databases by therapeutic area and mechanism
• Score opportunities by fit, award size, and effort
• Analyze past winner patterns for strategic advantage

Reviews expense data, flags policy violations, generates weekly spend briefs, identifies savings opportunities, and forecasts budget variance.

• Generate weekly spend briefs by department and vendor
• Flag policy violations and anomalies automatically
• Identify duplicate SaaS tools and underutilized subscriptions

Analyzes NDAs, MSAs, SOWs, and licensing agreements. Extracts material terms, flags risks, recommends routing, and drafts redlines.

• Extract all material terms from any contract
• Flag high-risk clauses (uncapped liability, IP issues, auto-renewal traps)
• Recommend approval routing based on contract type and value

Maps the patent landscape for any compound class or target, supports freedom-to-operate analysis, monitors competitor filings, and advises on exclusivity strategies — CoM, method of use, formulation, and regulatory data exclusivity.

• Patent landscape mapping (composition of matter, method of use, formulation)
• Freedom-to-operate framework and risk stratification
• Competitor patent monitoring and filing trend analysis

Synthesizes clinical, regulatory, IP, and commercial data into BD diligence assessments — from initial opportunity screening to full diligence memoranda, deal structure benchmarking, and risk-adjusted NPV frameworks — enabling faster, better-informed in-licensing and partnership decisions.

• 3-phase asset diligence framework (screening → initial → full diligence)
• Clinical data quality scoring and regulatory risk assessment
• Deal structure benchmarking by asset stage (upfront, milestones, royalties)

Summarizes transcripts into action registries, drafts decision-focused agendas, extracts owners and deadlines, and sends structured follow-ups.

• Summarize meeting transcripts into decisions + action items
• Draft purpose-built agendas for any meeting type
• Identify unowned actions and unresolved decisions

Drafts investor updates, board memos, press releases, job descriptions, all-hands talking points, and scientific lay summaries.

• Draft investor quarterly updates with pipeline, financials, and asks
• Write press releases for clinical milestones
• Create job descriptions with inclusive, compelling language

Generates pre-meeting briefs for CEO investor conversations — investor profile, prior meeting summary, calibrated talking points, and likely Q&A — so every conversation starts warm, not cold.

• Pre-meeting brief: investor profile, prior conversation summary, talking points
• Synthesize investor thesis and portfolio signals into actionable intelligence
• Generate likely questions + suggested responses calibrated to this investor

Drafts CEO letters, pipeline RAG narratives, decision memos, and board minutes — turning every board meeting into a governance event with clear decisions, owners, and follow-through.

• CEO letter and opening memo for every board meeting
• Pipeline status narratives in RAG format (Red/Amber/Green per program)
• Strategic decision memos framing options with tradeoffs

Produces slide-by-slide content outlines for investor presentations, corporate overviews, pipeline updates, and conference materials — narrative-first so teams spend time on design, not blank slides.

• Full corporate overview / investor pitch deck (12–16 slides)
• Pipeline update decks for existing investors (quarterly cadence)
• Conference presentations tailored to JP Morgan, ASCO, BIO, partnering events

Drafts press releases, shareholder letters, milestone announcements, and crisis communications with the disclosure precision life sciences requires and the clarity investors and media actually read.

• Press releases for clinical milestones, financing, regulatory designations, and partnerships
• Shareholder and investor letters (quarterly and event-driven)
• Website and pipeline copy refresh

Produces the recurring written outputs that keep investors informed, teams aligned, and external audiences current — from monthly investor emails to all-hands narratives to conference one-pagers.

• Monthly investor email updates (400 words, one specific ask)
• All-hands communications — quarterly updates, difficult topics, leadership transitions
• Pipeline table and website copy updates

Synthesizes published literature on any target, compound, or mechanism. Grades evidence quality, maps knowledge gaps, and delivers decision-ready research summaries.

• Synthesize literature with Oxford CEBM evidence grading
• Map competitive compound landscapes from published data
• Flag contradictions, replication failures, and methodological weaknesses

Maps the known compound landscape for any drug target — chemotypes, bioactivity, ADMET liabilities, patent positioning, and white space for differentiation.

• Target validation and druggability assessment
• Competitive compound landscape mapping by chemotype
• SAR pattern analysis and activity cliff identification

Analyzes HTS datasets to identify confirmed hits — applying PAINS/assay artifact filters, Z-prime quality assessment, dose-response confirmation criteria, and chemical series clustering — producing prioritized hit lists with chemical series scorecard output.

• HTS data quality assessment (Z', Z-factor, signal window, hit rate analysis)
• PAINS and assay artifact filter application (pan-assay interference compounds)
• Dose-response confirmation criteria and IC50 curve quality scoring

Guides lead optimization campaigns using multi-parameter optimization (MPO) frameworks, SAR analysis and matched molecular pair analysis, bioisostere libraries, and ADMET liability mitigation — driving toward development candidate nomination.

• Multi-parameter optimization (MPO) scoring framework design
• SAR interpretation and matched molecular pair (MMP) analysis
• Bioisostere suggestions for ADMET liability mitigation

Drafts complete experimental protocols from objectives to statistics, or critiques existing protocols with a structured scorecard and actionable redlines.

• Draft full protocols in 10-section SMART format
• Calculate required sample sizes with power justification
• Score existing protocols on rigor, reproducibility, and compliance

Governs research data infrastructure — ELN policy, compound registration standards, FAIR data principles, IP protection workflow (witnessed notebook entries), and research data management plans (RDMP) for regulated and non-regulated environments.

• ELN governance policy: IP protection, witness workflow, legal hold procedures
• Compound registration standards (structure, batch, inventory, purity)
• FAIR data principles implementation (Findable, Accessible, Interoperable, Reusable)

Interprets preclinical pharmacokinetic data, applies allometric scaling to predict human CL/Vd/t1/2, designs PK/PD relationships, and calculates first-in-human starting doses using NOAEL-based, MABEL, or receptor occupancy methods.

• PK parameter interpretation and cross-species comparison tables
• Allometric scaling for human CL, Vd, and t1/2 prediction
• First-in-human starting dose calculation (NOAEL-based, MABEL, receptor occupancy)

Designs GLP nonclinical safety study packages for IND submissions — species selection, dose setting, study duration requirements, genotoxicity and reproductive tox strategy — and drafts toxicology study report narratives aligned with ICH M3(R2), S1–S9 guidelines.

• IND-enabling nonclinical study package design (ICH M3(R2) / S9 for oncology)
• Species selection and dose-setting methodology (MTD, HNSTD, NOAEL, MABEL)
• GLP study design across general tox, geno, repro, and safety pharmacology

Designs translational biomarker strategies from preclinical through Phase 3 — PD, predictive, prognostic, and safety biomarker roadmaps, companion diagnostic (CDx) development pathways, liquid biopsy strategy, and regulatory biomarker qualification.

• Biomarker strategy framework (FDA/NIH BEST classification: PD, predictive, prognostic, safety)
• Biomarker roadmap from preclinical through Phase 3 registration
• Companion diagnostic (CDx) development pathway and regulatory strategy

Designs and interprets bioinformatics analyses — bulk RNA-seq DEG pipelines, scRNA-seq cell type analysis, CRISPR screen data with MAGeCK, GSEA/ORA pathway enrichment — and mines public datasets (TCGA, GTEx, DepMap) for target validation.

• Bulk RNA-seq differential expression analysis (FastQC → alignment → DESeq2 pipeline)
• scRNA-seq analysis pipeline (QC, clustering, cell type annotation, trajectory)
• CRISPR screen analysis with MAGeCK (essential genes, hit identification)

Designs clinical trial protocols from scratch or critiques existing ones — endpoint selection with FDA acceptance evidence, statistical power, inclusion/exclusion criteria, and feasibility scoring against ICH E8(R1).

• Design Phase 1–3 trial protocols with endpoint precedent from approved trials
• Statistical power calculations with explicit assumptions
• Inclusion/exclusion criteria optimization for enrollment feasibility

Designs group sequential, platform, seamless Phase 2/3, and Bayesian adaptive trials with pre-specified stopping rules, type I error control, and simulation requirements that satisfy FDA and EMA scientific advice expectations.

• Group Sequential Design (O'Brien-Fleming, Pocock, Lan-DeMets alpha spending)
• Platform and master protocol design (basket, umbrella, MAMS)
• Seamless Phase 2/3 design with combination test statistics

Scores investigator sites across 5 dimensions — therapeutic area expertise, enrollment track record, patient access, operational reliability, and activation speed — producing a ranked Tier 1/2/3 site list.

• 5-dimension site scoring framework (100-point scale)
• Competing trial conflict analysis per investigator
• Geographic optimization against patient population density

Manages the site startup checklist — IRB/IEC approvals, CTAs, regulatory documents, training — and drafts site communications, escalation emails, and site initiation visit agendas to compress activation timelines.

• Essential document checklist tracking (1572, CVs, IRB, CTA, lab certs)
• Activation milestone tracker with critical path identification
• Draft site activation reminders and escalation emails

Models enrollment rates from ClinicalTrials.gov historical data, applies adjustment factors for eligibility and biomarker selection, and produces scenario forecasts with explicit P50/P80 timelines.

• Benchmark enrollment rates from comparable historical trials (with NCT IDs)
• Adjust for eligibility stringency, biomarker selection, and competing trials
• Optimistic / base / conservative scenario modeling with stated assumptions

Translates trial eligibility criteria into addressable patient numbers using ICD-10 mapping, eligibility filter cascades, and biomarker prevalence data — answering the enrollment feasibility question before site selection.

• ICD-10 code mapping from indication description
• Eligibility filter cascade: diagnosed → treated → eligible → addressable
• Biomarker prevalence adjustment (PDL1, KRAS, MSI-H, HER2, etc.)

Designs patient recruitment strategies matched to the indication and patient type, drafts IRB-approvable recruitment materials, analyzes screen failure root causes, and builds retention plans.

• Multi-channel recruitment strategy tailored to indication and patient type
• Draft IRB-approvable patient-facing materials (posters, digital ads, physician letters)
• Screen failure root cause analysis with amendment recommendations

Maps the competitive trial landscape for any indication, benchmarks endpoints, identifies top enrolling sites, and builds enrollment timeline models.

• Map all active/recruiting trials by indication and mechanism
• Benchmark primary and secondary endpoints across comparable trials
• Identify top enrolling sites and leading KOLs

Drafts site activation letters, monitoring report summaries, protocol deviation reports, CAPA plans, and vendor escalation communications — all ICH E6(R2) compliant.

• Draft site communications (activation, reminders, escalations)
• Classify and document protocol deviations (major vs. minor)
• Write CAPA plans with root cause analysis and effectiveness checks

Supports medical monitors with safety data review plans, SAE reconciliation, DSMB meeting packages, dose escalation DLT review, and individual SAE medical assessment narratives.

• Safety monitoring plan design (ICH E6(R2)/(R3) compliant)
• DSMB charter drafting and meeting package preparation
• SAE reconciliation (clinical EDC vs. safety database)

Designs CDASH v2.0-compliant CRFs, authors Data Management Plans, builds edit check specifications, manages external data reconciliation, and coordinates database lock procedures across all data streams.

• CDASH v2.0 compliant CRF design and annotation
• Data Management Plan authoring (all 12 sections)
• Edit check specification development (range, consistency, cross-form checks)

Designs the full CDISC standards implementation plan — CDASH to SDTM to ADaM — including controlled terminology management, Pinnacle21 validation strategy, and FDA/EMA submission package organization.

• CDISC implementation plan from CDASH through SDTM to ADaM
• Controlled terminology (CT) version management and mapping
• Pinnacle21 validation strategy and common error prevention

Architects CDISC-compliant SDTM and ADaM datasets, writes define.xml 2.1 structures, guides Pinnacle21 validation remediation, and produces annotated CRF and Reviewer's Guide specifications for NDA/BLA submissions.

• SDTM domain mapping and implementation guide compliance
• ADaM dataset design (ADSL, ADAE, ADTTE, ADLB, ADCM, ADRS)
• define.xml 2.1 structure and metadata documentation

Drafts Statistical Analysis Plans using the ICH E9(R1) estimand framework, designs TLF specifications, calculates power and sample size with full assumption documentation, and advises on multiplicity, missing data, and adaptive design statistical strategy.

• SAP drafting with ICH E9(R1) estimand framework (all 5 components)
• Power and sample size calculation with sensitivity analysis across assumptions
• Multiplicity adjustment strategy (hierarchical, Bonferroni, Hochberg, Dunnett)

Designs tiered data review programs (DRP), manages query lifecycle tracking, coordinates SAE reconciliation, identifies CSM signals from data patterns, and builds database lock readiness checklists across all data streams.

• Tiered Data Review Program design (Central Statistical, Clinical, Site-level)
• Query lifecycle management with aging reports and resolution tracking
• SAE reconciliation coordination (clinical EDC vs. safety database)

Manages the database lock process from T-20 weeks through lock and post-lock amendments — tracking all data streams, coordinating readiness assessments across EDC, external data, SAE reconciliation, and medical coding — through submission dataset delivery.

• Data lock timeline planning (T-20 weeks backward from lock date)
• Multi-stream readiness assessment (EDC, lab, ePRO, ECG, PK, biomarker, SAE)
• Interim analysis snapshot coordination and blinding controls

Specifies TLF catalogs aligned to ICH E3 requirements, designs shell tables for safety, efficacy, and PK outputs, writes Kaplan-Meier and forest plot specifications, and annotates shell outputs for programming.

• TLF catalog design (safety, efficacy, PK, demographics — ICH E3 aligned)
• Safety table shells: AE summary, TEAEs by SOC/PT, deaths, discontinuations
• Efficacy table shells: response rates, time-to-event, subgroup analyses

Analyzes regulatory pathways, designation opportunities, and agency precedents. Builds pre-IND meeting packages, risk registers, and data package strategies.

• Regulatory pathway analysis with approval precedents
• Breakthrough, Fast Track, Orphan, and RMAT designation strategy
• Pre-IND and Type A/B/C meeting package development

Designs global regulatory strategies for FDA, EMA, PMDA, Health Canada, TGA, and beyond — parallel submission sequencing, Project Orbis eligibility, reliance pathway opportunities, and agency-specific data requirements.

• Multi-market pathway comparison (FDA, EMA, PMDA, TGA, Health Canada, ANVISA, NMPA)
• Parallel submission sequencing strategy with timeline analysis
• Project Orbis eligibility assessment (oncology simultaneous review)

Designs pediatric development programs under PREA, BPCA, and EMA PIP requirements — PSP development, waiver/deferral strategy, PK bridging approach, and age-appropriate formulation planning for FDA and EMA submissions.

• PREA obligation assessment and Pediatric Study Plan (PSP) development
• Full/partial waiver and deferral strategy with FDA rationale
• EMA Pediatric Investigation Plan (PIP) development and timeline

Navigates FDA Orphan Drug Designation, EMA orphan eligibility, and global rare disease incentives — prevalence analysis, plausible hypothesis documentation, ODD application drafting, and exclusivity management strategy.

• FDA ODD application development (prevalence data + plausible hypothesis)
• EMA Orphan Designation criteria and significant benefit strategy
• 7-year US and 10-year EU exclusivity management and competitor monitoring

Drafts IND, NDA, BLA, and IB sections using ICH-compliant structure. Each output includes a data gaps list and reviewer notes for RA professional review.

• Draft Module 2.7 clinical summaries (ISS/ISE frameworks)
• Write Investigator's Brochure sections
• Draft Clinical Study Report safety and efficacy sections

Manages post-approval commitments — PMC/PMR tracking, REMS program implementation and assessment, Phase 4 study design, periodic safety reporting, and label update strategy for efficacy expansion and safety revisions.

• PMC/PMR tracking system and annual FDA status reporting
• REMS implementation, periodic assessment, and modification strategy
• Phase 4 / post-approval confirmatory study design

Manages the 12-month pre-submission process for NDA/BLA — CTD module checklist, eCTD technical requirements, RTF risk assessment, pre-NDA meeting preparation, and submission day execution.

• 12-month pre-submission timeline and milestone tracking
• CTD module gap analysis across all five modules
• eCTD technical conformance and Pinnacle21 validation requirements

Prepares FDA Type A/B/C and EMA Scientific Advice packages — meeting type selection, briefing document structure, precision question formulation, agency position anticipation, and post-meeting minute review strategy.

• FDA meeting type selection (Type A/B/C) with scheduling strategy
• Briefing document drafting (Cover, Background, Questions, Appendices sections)
• Question formulation for binary/constrained answers with fallback positions

Monitors and synthesizes FDA, EMA, PMDA, and global regulatory actions — approvals, CRLs, clinical holds, guidance documents, and advisory committee outcomes — and delivers tiered intelligence briefs that identify strategic implications before competitors do.

• FDA regulatory action tracking (approvals, RTFs, CRLs, clinical holds, 483s)
• Guidance document monitoring and gap analysis for active programs
• Advisory Committee (AdCom) pre-hearing briefing and voting pattern analysis

Drafts USPI sections in FDA PLR format, benchmarks proposed language against approved labels in the same class, and provides labeling negotiation strategy — including REMS assessment and Boxed Warning analysis.

• Full USPI drafting per 21 CFR 201.56/201.57 PLR format
• Section drafting: Indications, Dosage, Warnings, Adverse Reactions, Clinical Studies
• Benchmarking proposed label against 2–3 approved same-class products

Drafts CIOMS-format individual case safety report narratives, assesses expedited reporting obligations, provides MedDRA coding guidance, and builds DSMB/DMC briefing documents.

• Draft 15-box CIOMS format SAE narratives from raw case data
• Expedited reporting assessment (7-day vs. 15-day vs. non-expedited)
• MedDRA preferred term and SOC coding guidance

Designs MedDRA query strategies (SMQs, CMQs), applies CIOMS-8 aggregate data methodology, produces ICH E3-compliant adverse event tables, and guides safety database quality checks and SAE reconciliation.

• MedDRA query design (SMQ broad/narrow, custom MedDRA queries)
• Aggregate AE table production (ICH E3 format, incidence rates, EAIR)
• CIOMS-8 methodology for exposure-adjusted safety analysis

Designs disproportionality analyses (PRR, ROR, BCPNN, EBGM) across FAERS, VigiBase, and EVDAS. Validates signals using Bradford Hill criteria, drafts GVP Module IX signal assessment memos, and produces escalation-ready recommendations.

• Disproportionality analysis design (PRR, ROR, IC025, EBGM05)
• Signal validation using Bradford Hill criteria and clinical plausibility
• GVP Module IX signal assessment memo drafting

Produces aggregate pharmacovigilance documents — DSUR, PSUR/PBRER, and signal assessment memos — in ICH E2C/E2F format, with correct reporting timelines, exposure-adjusted tables, and SUSAR determinations.

• DSUR annual safety update drafting (ICH E2F — all sections)
• PSUR/PBRER structure and benefit-risk section drafting (ICH E2C(R2))
• Signal detection documentation and signal assessment memos

Designs GVP Module VI compliant literature monitoring strategies, assesses publications for ICSR case-qualifying criteria, determines expedited reporting obligations, and maintains audit-ready screening logs.

• Literature monitoring strategy design (source, frequency, search strings)
• ICSR case-qualifying assessment against ICH E2D 4-element criteria
• Expedited reporting obligation determination (7-day / 15-day / periodic)

Drafts EU Risk Management Plans (GVP Module V), designs proportionate REMS programs, authors HCP and patient risk-minimization materials, and advises on PASS study design and RMP update strategy.

• EU-RMP drafting — all parts including Safety Specification and PV Plan
• Safety concern classification (Important Identified / Important Potential / Missing Information)
• REMS design — argue against unnecessary elements or design proportionate ETASUs

Guides biologic and small molecule process development — DOE design, QbD design space, scale-up strategy, tech transfer packages, and ICH Q8/Q11 compliance across upstream and downstream unit operations.

• Upstream process development: cell line, media, feed strategy, bioreactor parameters
• Downstream process development: chromatography, filtration, formulation
• DOE design (factorial, RSM, OFAT) with critical process parameter identification

Designs analytical method development strategies for biologics and small molecules — HPLC, CE, SEC, DLS, potency assays — and drafts ICH Q2(R2) validation protocols, stability programs per ICH Q1A, and specification-setting strategies.

• Analytical method development strategy for biologics and small molecules
• ICH Q2(R2) validation protocol design (all parameters with acceptance criteria)
• Stability program design per ICH Q1A — storage conditions, time points, attributes

Manages clinical supply chain strategy — CDMO selection, demand forecasting, cold chain design, temperature excursion protocols, supply risk registers, and IMP release logistics — from Phase 1 through commercial launch readiness.

• Clinical supply demand forecasting with overage calculations
• CDMO selection framework: RFI scoring, due diligence, governance model
• Cold chain design and carrier qualification strategy

Classifies manufacturing deviations (critical/major/minor), guides OOS investigations per FDA 2006 guidance, designs CAPA frameworks with effectiveness checks, and supports batch record review — keeping GMP operations compliant without over-escalating.

• Deviation classification (critical / major / minor) with impact assessment
• OOS investigation workflow (Phase 1 lab + Phase 2 full manufacturing investigation)
• CAPA plan design with root cause analysis (5 Whys, Ishikawa)

Guides batch record review, OOS investigation workflows per FDA 2006 guidance, out-of-trend analysis, stability program oversight, and Certificate of Analysis standards — keeping QC operations compliant and release timelines intact.

• Batch record review checklist and discrepancy identification
• OOS investigation workflow (Phase 1 lab + Phase 2 full investigation per FDA 2006)
• Out-of-trend analysis and action limit trigger assessment

Navigates ICH Q8–Q12 CMC regulatory strategy — from IND-stage manufacturing controls through NDA/BLA submission readiness, manufacturing change classification, and comparability protocol design.

• CMC development stage requirements (IND → Phase 3 → NDA/BLA)
• ICH Q8/Q9/Q10/Q11/Q12 guideline application and gap analysis
• Manufacturing change classification (PAS / CBE-30 / ARC)

Identifies and tiers key opinion leaders (national/regional/local) by publication volume, trial PI activity, and congress presence. Maps co-authorship networks, designs MSL territory coverage, and advises on advisory board composition strategy.

• KOL tiering (Tier 1/2/3) by publication, trial, and congress activity
• Scientific influence network mapping (co-authorship, institutional affiliations)
• MSL territory design with KOL assignment priorities

Designs MSL engagement plans for Tier 1/2/3 KOLs — reactive vs. proactive exchange frameworks, insight capture templates, IIS evaluation criteria, and territory coverage optimization for pre-launch and post-approval medical affairs teams.

• KOL engagement plan design with 12-month scientific exchange objectives
• Reactive vs. proactive exchange boundary documentation and training
• Insight capture and aggregation template for medical affairs intelligence

Drafts standard response letters (SRLs) for on-label and unsolicited off-label medical information requests, builds FAQ libraries for launch readiness, drafts AMCP dossier sections for payer audiences, and ensures every output is FDA-compliant with appropriate off-label disclosure.

• Standard response letter drafting (on-label and unsolicited off-label)
• Off-label disclosure language and regulatory compliance framing
• AMCP dossier format for payer medical information requests

Designs publication plans that maximize clinical impact, drafts congress abstracts for ASCO/ESMO/ASH and other major meetings, advises on authorship strategy and ICMJE compliance, and manages embargo coordination with regulatory submissions.

• Publication plan design (congress sequence → full manuscript strategy)
• Congress abstract drafting (ASCO, ESMO, ASH, AACR, AAN, and more)
• Journal selection strategy with submission sequencing

Designs post-launch real-world evidence studies — comparative effectiveness with propensity score methods, burden of illness, treatment patterns, and adherence studies — using claims, EHR, and registry data for payer, HTA, and guideline committee audiences.

• Comparative effectiveness study design (active comparator, new user design, IPTW)
• Data source selection and feasibility assessment (claims, EHR, registry)
• Indirect treatment comparison and MAIC for non-head-to-head payer evidence

Designs US and global market access strategy — formulary positioning, step-edit and PA criteria framework, HTA submission planning (NICE, G-BA, HAS, CADTH), value dossier structure, and pricing strategy with gross-to-net modeling.

• US payer landscape analysis (commercial, Medicare Part B/D, Medicaid)
• Formulary tier strategy and PA/step-therapy criteria design
• HTA submission planning (NICE QALY framework, G-BA AMNOG, HAS, CADTH)

Designs health economics and outcomes research evidence — cost-effectiveness models (Markov, partitioned survival), budget impact models, PRO instrument strategy, indirect treatment comparisons (NMA/ITC), and post-launch RWE study plans for payer and HTA audiences.

• Cost-effectiveness model design (oncology partitioned survival, chronic disease Markov)
• Budget impact model construction (3-year, per-1,000 member, payer perspective)
• EQ-5D and PRO instrument selection and trial implementation strategy

Builds patient-funnel revenue forecasts from epidemiology through net realized price — market share ramp modeling with launch analogs, gross-to-net waterfall construction, and bear/base/bull scenario analysis for investor, board, and internal planning.

• Epidemiology-based patient funnel (prevalence → eligible → treated → share)
• Market share ramp modeling with launch analog benchmarking
• Gross-to-net waterfall (Medicaid, commercial, Part D, 340B, GPO)

Drafts FDA-compliant HCP-facing content — sales aids, leave-behinds, e-detailing modules, congress booth copy, and speaker program materials — with claim matrix validation, fair balance, and MLR-ready structure.

• Promotional content drafting (sales aids, leave-behinds, e-detailing, digital)
• Claim matrix validation against approved label
• Fair balance and ISI integration per OPDP requirements

Equips commercial field teams — TBMs, KAMs, and MSLs — with pre-call planning briefs, objection handling scripts, payer pull-through tools, and territory prioritization frameworks for every physician interaction.

• Pre-call planning briefs (prescriber profile, call objective, key message selection)
• Objection handling scripts for safety, access, and competitive challenges
• Payer pull-through tools (PA navigation, formulary status, co-pay messaging)

Builds and tracks the complete launch readiness program — field force hiring and training, payer coverage milestones, patient hub go-live, specialty pharmacy contracting, and day-1 deployment plans — across all commercial functions.

• 18-month / 12-month / 90-day launch readiness tracker across all functions
• Sales force size-of-force analysis and territory design
• Patient hub program design and go-live milestone planning

Produces weekly competitive intelligence briefs, drafts board and investor communications, and builds strategic decision frameworks — all in the format that executives actually read.

• Weekly competitive intelligence briefs (pipeline, regulatory, deals)
• Draft investor quarterly updates and board package narratives
• Build strategic decision frameworks (build vs. buy vs. partner)